Payment overview · 2025
General Payments
$278.58
13 reported records · 6 companies
Healthcare provider profile · identity verified
Kelli J Dumm, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLESTON, WV · NPI 1760461164
Verified facts
What the public records show
CMS Open Payments records show Kelli J Dumm, MD received $278.58 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.63 | 41.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.06 | 24.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.92 | 13.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.76 | 9.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.33 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.88 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.58 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.91 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.19 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 597 | 143 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 506 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 119 |
| Gabapentin | Gabapentin | 378 | 75 |
| Lisinopril | Lisinopril | 368 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 356 | 105 |
| Omeprazole | Omeprazole | 342 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 98 |
| Losartan Potassium | Losartan Potassium | 295 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 82 |
| Montelukast Sodium | Montelukast Sodium | 264 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 63 |
| Tramadol Hcl | Tramadol Hcl | 219 | 44 |
| Furosemide | Furosemide | 208 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 41 |
| Glipizide Er | Glipizide | 179 | 42 |
| Buspirone Hcl | Buspirone Hcl | 176 | 36 |
| Eliquis | Apixaban | 171 | 41 |
| Alprazolam | Alprazolam | 170 | 37 |
| Potassium Chloride | Potassium Chloride | 166 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 44 |
| Trazodone Hcl | Trazodone Hcl | 162 | 34 |
| Clonazepam | Clonazepam | 153 | 29 |
| Irbesartan | Irbesartan | 133 | 39 |
| Ozempic | Semaglutide | 132 | 23 |
| Sertraline Hcl | Sertraline Hcl | 126 | 40 |
| Carvedilol | Carvedilol | 125 | 30 |
| Temazepam | Temazepam | 121 | 21 |
| Januvia | Sitagliptin Phosphate | 120 | 28 |
| Synthroid | Levothyroxine Sodium | 115 | 28 |
| Famotidine | Famotidine | 113 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 18 |
| Simvastatin | Simvastatin | 108 | 33 |
| Allopurinol | Allopurinol | 106 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 30 |
| Lorazepam | Lorazepam | 103 | 20 |
| Jardiance | Empagliflozin | 102 | 28 |
| Pregabalin | Pregabalin | 102 | 19 |
| Metformin Hcl | Metformin Hcl | 101 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 20 |
| Bupropion Xl | Bupropion Hcl | 95 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 38 |
| Meloxicam | Meloxicam | 93 | 28 |
| Cefuroxime | Cefuroxime Axetil | 91 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 19 |
| Diazepam | Diazepam | 85 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 37 |
| Glimepiride | Glimepiride | 81 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 20 |
| Prednisone | Prednisone | 79 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 14 |
| Ezetimibe | Ezetimibe | 67 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 24 |
| Clonidine Hcl | Clonidine Hcl | 60 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 15 |
| Spironolactone | Spironolactone | 56 | 18 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 15 |
| Metformin Hcl Er | Metformin Hcl | 50 | 16 |
| Celecoxib | Celecoxib | 49 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Naproxen | Naproxen | 49 | 11 |
| Amoxicillin | Amoxicillin | 48 | 33 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Valacyclovir | Valacyclovir Hcl | 46 | 20 |
| Azithromycin | Azithromycin | 44 | 29 |
| Cefdinir | Cefdinir | 44 | 36 |
| Mounjaro | Tirzepatide | 44 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Fluconazole | Fluconazole | 38 | 28 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Nystatin | Nystatin | 34 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 13 |
| Linzess | Linaclotide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 12 |
| Colchicine | Colchicine | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Zaleplon | Zaleplon | 25 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 11 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.58 · 13 records | Novo Nordisk Inc | Auvelity, BEXSERO, Kerendia, NURTEC ODT, Ozempic, PEDIARIX, QULIPTA, ROTARIX, Rybelsus, SYNTHROID, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error